Ryan Gessner, Ph.D.
Co-founder and CEO
With over 10 peer-reviewed manuscripts in high resolution ultrasonic imaging of vasculature, Dr. Gessner leads product development efforts for SonoVol’s next gen imaging scanner. In 2013 he was awarded both the Distinguished Dissertation award and the Lineberger Cancer Center’s Graduate Fellow Award in Basic Sciences. He currently serves as PI on two Phase II SBIRs through the NSF and NCI.
Paul Dayton, Ph.D.
Co-founder and CTO
Paul Dayton is Professor and Associate Chair in the UNC-NCSU Joint Department of Biomedical Engineering. Dr. Dayton brings over 17 years of ultrasound engineering experience to SonoVol’s technical team, and has published over 120 papers and book chapters in the field of ultrasonic imaging. The Dayton lab currently employs 18 students and staff members working towards new ultrasound imaging and ultrasound-mediated therapeutics technologies, with a primary focus on improving cancer detection and assessment approaches.
Don Rose, Ph.D.
Don Rose is the Director of UNC’s Carolina KickStart Program (formerly NC BioStart). Prior to that, he held senior leadership roles at a number of life science startups, and was a general partner with Catalysta Partners (now Hatteras Venture Partners). Dr. Rose was co-founder and VP of Research and Development for Cartesian Technologies, a leader in instrumentation for DNA microarrays and nanoliter dispensing. Dr. Rose received his Ph.D. in Analytical Chemistry and BS in Nutrition from the University of North Carolina. He has published eight papers, two book chapters, and holds six US patents.
Tomek Czernuszewicz, Ph.D.
Rajalekha Manjakuppam Rajamahendiran
Board of Advisors
Peter C. Johnson, MD
Peter serves as the chairman of the advisory board for SonoVol, with an expertise focused in the regenerative medicine space. In the 1990s Peter was Founder and President of the Pittsburgh Tissue Engineering Initiative, and later cofounded TissueInformatics, which developed a suite of tissue analysis software products. He has served as an executive at a number of other biotech companies, serves as co-editor in chief of the journal Tissue Engineering for over a decade, and is an Adjunct Professor at UNC’s Kenan Flagler Business School, the UNC Department of Surgery, the joint NC State/UNC Department of Biomedical Engineering and the Wake Forest Institute of Regenerative Medicine. He is presently a co-founding Principal at MedSurgPI, LLC.
Trent has dedicated the last 18 years of his professional life to the clinical and commercial side of biotechnology, clinical medicine, medical device, molecular imaging and information system markets. These years have been spent in government and corporate environments ranging from the U.S. Navy, private family-owned biotechnology start-ups, to multibillion-dollar public technology companies. He is currently the Senior Discovery Services Manager at Perkin Elmer.
Dr. Rosol is the Head of the Translational Imaging Group at Novartis Pharmaceuticals. He brings over 15 years of preclinical imaging experience in both academic and industry settings. His training and experience are in the fields of biophysics, physiology and biological/medical imaging, and his past research focused on cardiovascular imaging, and image reconstruction as applied to muscle physiology and animal models of cancer and stem cell biology. He has also directed two academic core imaging facilities.
Dr. Willis is an associate professor and Vice Chair for Academic Affairs in the Department of Pathology and Laboratory Medicine at UNC Chapel Hill. In addition to being a Principal Investigator within the McAllister Heart Institute, Dr. Willis is the Director of several different facilities on campus, including the Campus Health Services Laboratory, and Assistant Director of the Clinical Core Laboratory. His research is focused on heart failure and cardiac metabolism, and has over 10 years of echocardiographic experience.
Dr. Willmann is a board certified radiologist, and the Principal Investigator of the Translational Molecular Imaging Laboratory at Stanford University. His laboratory focuses on developing clinically translatable molecular and functional imaging biomarkers with special focus on pancreatic, liver, renal, ovarian, and prostate cancers. As a clinician-scientist with over 20 papers published in the last 10 years, Dr. Willmann is a leading expert in both clinical and preclinical cancer assessment with ultrasound.